Worldwide End Stage Renal Disease Industry to 2026 – Increasing Number of Patients Suffering from Chronic Kidney Disease is Driving Growth –

20-Jan-2022 Intellasia | BusinessWire | 11:09 PM Print This Post

DUBLIN--(BUSINESS WIRE)--The "End Stage Renal Disease Market - Growth, Trends, Covid-19 Impact, and Forecasts (2021 - 2026)" report has been added to's offering.

The End-Stage Renal Disease Market is expected to grow at a CAGR of around 10% during the forecast period.

Companies Mentioned

  • Philips Healthcare
  • GE Healthcare
  • Siemens Healthineers
  • Cooper Surgicals Inc
  • MedGyn Products, Inc
  • Edan Instruments
  • Sunray Medical Apparatus Co.
  • Bionet America
  • Trismed CO, Ltd
  • Mindray Medicals
  • Fujifilm Sonosite, Inc
  • Natus Medical, Inc

Key Market Trends

Dialysis Segment by Treatment is Expected to Witness a High Growth Over the Forecast Period

Dialysis is a procedure that removes waste products from the blood, such as urea and creatinine, as a result of inadequate kidney function. It is frequently required for persons with chronic renal failure. The blood is cleansed, and extra fluid and toxins are eliminated during this operation.

Moreover, the demand for dialysis is expected to increase as the incidence of end-stage renal disease increases across the world. The prevalence of end-stage renal disease (ESRD) is high and increasing at a significant rate. According to The U.S. Renal Data system report of 2020, the number of patients with incident ESRD in 2018 was 131,636, an increase of 2.3% since 2017. Between 2017 and 2018, unadjusted ESRD incidence per million increased by 1.5%, while adjusted ESRD incidence per million increased by only 0.2%.

The number of patients with incident ESRD who initiated in-center hemodialysis ranged from 111,000 to 113,000 for the fourth consecutive year in 2018. Meanwhile, the number of patients who initiated peritoneal dialysis and who received a preemptive transplant reached an all-time high of 18,631. Additionally funding for dialysis is rising in the U.S., according to the American Society of Nephrology.

Asia-Pacific is Expected to Witness a High Growth Over the Forecast Period

Asia-Pacific is expected to witness a high growth in end-stage renal disease due to the presence of high disposable income, and the high acceptance rate of technologically improved products. Moreover, high blood pressure and diabetes cases in the Asia Pacific region may also contribute to the market growth. According to Asian Diabetics Prevention Initiatives, in 2020, 60% of the diabetic population in the world lived in Asia, with a higher contribution in China and India, which is 113.9 million and 65.1 million adults with diabetes, respectively. By 2030, both China and India combined will have almost half a billion diabetic patients.

Additionally, growing patient affordability, aging population, lifestyle stress, a broad population base, and improving diagnosis quality will also fuel the market growth. A report published by the national health portal of the Indian Government estimates that every year about 2.2 Lakh new patients of end-stage renal disease (ESRD) are increasing, resulting in demand for 3.4 Crore dialysis every year. Approximately 4950 dialysis centers were available, largely in the private sector in India. The presence of a large number of dialysis centers in this region and a rise in the number of patients with chronic renal and kidney diseases are expected to boost the market growth.

Key Topics Covered:





4.1 Market Overview

4.2 Market Drivers

4.2.1 Increasing Number of Patients Suffering from Chronic Kidney Disease

4.2.2 Introduction of Technologically Advanced Products

4.2.3 Rising Prevalence of Diabetes and Hypertension

4.3 Market Restraints

4.3.1 Delay in Diagnosis of Chronic Kidney Disease

4.4 Porter's Five Force Analysis


5.1 By Treatment

5.2 By Diagnosis

5.3 Geography


6.1 Company Profiles


For more information about this report visit

Laura Wood, Senior Press Manager
[email protected]

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900


Category: BusinessWire, PRAsia

Print This Post

Comments are closed.